ABSK051 / Abbisko - LARVOL DELTA

Abbisko Therapeutic announces the IND approval by China NMPA for novel small molecule CD73 inhibitor ABSK051 (Abbisko Therap Press Release) - "Abbisko Therapeutics Co., Ltd...today announced that ABSK051,a novel small molecule CD73 inhibitor, has obtained the clinical trial approval from the National Medical Products Administration (NMPA) of the People’s Republic of China. ABSK051 is about to enter the first-in-human (FIH) phase I clinical trial for the treatment of advanced solid tumors in China."

New P1 trial • Non-US regulatory • Oncology • Solid Tumor

A next-generation KRASG12C inhibitor ABSK071 demonstrated broad synergy with other therapeutic agents in KRASG12C mutated cancer models (AACR 2023) - "A set of immuno-oncology reagents, including anti-PD-1/L1, CSF-1R inhibitor (ABSK021) and CD73 inhibitor (ABSK051) were also tested in combination with ABSK071 in vivo using mouse syngeneic models. ABSK071 demonstrated much stronger inhibitory activity than sotorasib and adagrasib against a variety of cell lines harboring KRASG12C, as well as significantly better in vivo anti-tumor efficacy in xenograft models that were less sensitive to sotorasib. Synergistic effects on cell growth inhibition were observed in vitro with ABSK071 in combination with several agents including cetuximab, afatinib, AZD4547, TNO-155, RMC-4630 and BI3406... ABSK071 is a next-generation KRASG12C inhibitor with greater activity and anti-tumor efficacy in vitro and in vivo. It also demonstrated broad synergistic effects with a large set of targeted agents and immuno-oncology agents, indicating its strong potential in combinatory therapy in treating a wider range of KRASG12C-dependent cancers."

IO biomarker • Late-breaking abstract • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

A potent and selective small molecule antagonist of CD73 ABSK051 reverses immunosuppression through reduction of adenosine production (SITC 2022) - "It also demonstrated in vivo anti-tumor efficacy as a single agent in various preclinical tumor models and in combination with other immune-oncology agents. Conclusions Taken together, these data demonstrated desirable preclinical biological profile of ABSK051 against CD73 and in regulating tumor growth, paving the road for further development of it as a preclinical drug candidate and potential clinical evaluation as an immune agent for cancer patients."

Oncology • CD8 • NT5E • PSAP